What is the Bionexus Gene Lab Corp. stock price forecast?

Bionexus Gene Lab Corp. is currently trading at $2.14. View real-time AI analysis on Alpha Lenz.

What is Bionexus Gene Lab Corp. insider trading activity?

View the latest insider trading data for Bionexus Gene Lab Corp. on Alpha Lenz.

What is Bionexus Gene Lab Corp.'s P/E ratio?

Bionexus Gene Lab Corp.'s P/E ratio is -1.3.

Bionexus Gene Lab Corp.

NASDAQ · BGLC

$2.14+0.03(+1.42%)Pre-market

Ask about Bionexus Gene Lab Corp.'s future dividend policy...

Alpha Chat Insight

“Bionexus Gene Lab Corp. trades at a P/E of -1.3 (undervalued) with modest ROE of -35.2%.”

Ask for details →

Company Overview

Bionexus Gene Lab Corp. operates as a biotechnology company with a focus on the research and development of genomic sequencing and analysis solutions. Its primary function is to advance personalized medicine by utilizing its genetic technologies to assist healthcare professionals in identifying and customizing treatment plans for patients based on their unique genetic profiles. Notable features of Bionexus Gene Lab Corp. include its cutting-edge laboratory facilities and a comprehensive database of genetic information, which enable it to provide accurate and efficient genomic testing services. The company plays a significant role in the healthcare and biopharmaceutical sectors, impacting areas such as precision oncology, hereditary disease prevention, and drug development. By facilitating a deeper understanding of genetic predispositions and responses, Bionexus Gene Lab Corp. is integral to the evolution of targeted therapies and personalized healthcare treatments, reflecting its importance in advancing modern medical practices.

CEOMr. Su-Leng Tan

Websitehttps://www.bionexusgenelab.com

SectorBasic Materials

IndustrySpecialty Chemicals

Employees30

Company Statistics

FY 2025

Profile

$3.97MMarket Cap

$7.42MRevenue

0.00Shares Out

30Employees

Margins

14.62%Gross

-38.34%EBITDA

-42.54%Operating

-40.20%Pre-Tax

-40.20%Net

Valuation

-1.33P/E

0.46P/B

0.54EV/Sales

-0.04EV/EBITDA

-2.12P/FCF

Growth (CAGR)

-12.09%Rev 3Yr

-8.20%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-30.32%ROA

-35.24%ROE

-30.12%ROIC

Financial Health

$4.04MCash & Cash Equivalents

$-3.40MNet Debt

7.40%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Bionexus Gene Lab Corp. trades at a P/E of -1.3 (undervalued) with modest ROE of -35.2%.”

Ask for details →

Frequently Asked Questions

Bionexus Gene Lab Corp. (ticker: BGLC) is a company listed on NASDAQ in the Basic Materials sector (Specialty Chemicals). It has approximately 30 employees. Market cap is $4M.

The current price is $2.14 with a P/E ratio of -1.33x and P/B of 0.46x.

ROE is -35.24% and operating margin is -42.54%. Annual revenue is $7M.